Import from '@/components/mdx'

PT-141 (Bremelanotide) and Your Kidneys: Renal Protection, Renal Risk, and What Women Need to Know

What Is PT-141 (Bremelanotide) and Why Are Women Asking About Its Kidney Effects?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist that acts centrally, targeting MC3R and MC4R receptors in the hypothalamus to increase sexual desire. The FDA approved it in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike flibanserin, it is taken on demand rather than daily, which shapes its renal exposure profile considerably.

Women are asking about kidney effects for two converging reasons. First, bremelanotide causes a well-documented, transient rise in blood pressure after each dose, and sustained hypertension is a leading driver of chronic kidney disease (CKD) in women. Second, online communities and compounding pharmacies have circulated claims that PT-141 "protects" the kidneys through anti-inflammatory melanocortin pathways observed in rodent studies. That claim, applied to the approved human formulation at its approved dose and indication, is not supported by clinical data.

This article separates the preclinical signal from the clinical reality, and explains what the renal risk means for you depending on your life stage, your current blood pressure, and your kidney function.

The Melanocortin System and Kidney Biology: Where the "Renoprotection" Idea Comes From

The idea that melanocortin agonists might protect the kidney is not fabricated. Several MC1R and MC3R pathways genuinely suppress renal tubular inflammation in animal models.

Preclinical Evidence for Renoprotection

Rodent models of ischemia-reperfusion injury and cisplatin-induced nephrotoxicity show that alpha-melanocyte-stimulating hormone (alpha-MSH) and its analogs reduce tubular cell apoptosis, lower pro-inflammatory cytokine expression, and improve GFR recovery. A 2013 review in the American Journal of Physiology summarized this body of work, noting that MC1R activation on renal tubular epithelial cells attenuates NF-kB signaling after ischemic injury in rats.

Bremelanotide is an analog of alpha-MSH. It binds MC1R, MC3R, MC4R, and MC5R with varying affinity. The MC4R agonism drives both the desired central effect on libido and the unwanted cardiovascular side effects. The MC3R and MC1R activity is what underlies the theoretical anti-inflammatory renal story.

Why Rodent Data Does Not Translate Here

The doses used in rodent renoprotection studies are not equivalent to the 1.75 mg subcutaneous human dose. Extrapolating organ-protective effects from pharmacological animal models to a single on-demand human dose is a category error. No peer-reviewed human clinical trial has examined bremelanotide as a renoprotective agent. The FDA prescribing information makes no mention of renal benefit. Telling a patient with early CKD that PT-141 might protect her kidneys would be clinically irresponsible given available data.

A practical framework: preclinical melanocortin renoprotection is a hypothesis worth watching in future clinical trials. It is not a reason to prescribe or self-administer bremelanotide to a woman with kidney disease today.

Documented Renal Risks of Bremelanotide in Clinical Trials

The RECONNECT trials (two replicate phase 3 randomized controlled trials) enrolled 1,267 premenopausal women with HSDD and provided the key safety dataset that supported FDA approval. Results were published in Obstetrics & Gynecology in 2019.

Blood Pressure: The Primary Renal Concern

Every dose of bremelanotide produces a transient hemodynamic effect. In the RECONNECT program, mean maximum systolic blood pressure increased by approximately 6 mmHg and diastolic by approximately 3 mmHg, peaking within 12 hours of injection and resolving within 12 hours in most women. This sounds modest. For a woman with controlled hypertension at baseline, a 6 mmHg systolic spike per sexual encounter, repeated monthly, adds cumulative pressure exposure to glomerular capillaries over time. For a woman with CKD stage 3 or above, where blood pressure management directly controls the rate of GFR decline, this is not a trivial concern.

The FDA prescribing label carries a specific contraindication against use in women with known cardiovascular disease and a warning to measure blood pressure before administration. The label does not set a specific numeric cutoff for hypertension, which is a clinical gap.

Transient GFR Reduction

Phase 2 pharmacokinetic studies reported a mild, transient reduction in estimated glomerular filtration rate following subcutaneous administration of bremelanotide. This appears to be hemodynamically mediated, consistent with the blood pressure changes, rather than direct tubular toxicity. The eGFR effect was reversible and not clinically significant in women with normal baseline kidney function. However, the FDA label advises caution in women with severe renal impairment (eGFR <30 mL/min/1.73 m²) and states the drug has not been studied in women on dialysis.

Nausea, Vomiting, and Dehydration Risk

Nausea is the most common adverse effect of bremelanotide, reported in approximately 40% of women in the RECONNECT trials Obstet Gynecol 2019. Vomiting occurred in roughly 5%. Repeated dehydration episodes from vomiting can directly compromise renal perfusion, particularly in women who are already volume-depleted (for instance, postpartum women breastfeeding, or perimenopausal women with hot-flush-related insensible losses). This indirect pathway to renal stress is rarely discussed in prescriber communications but deserves attention in real-world clinical practice.

Hyperpigmentation and Melanocortin Receptor Saturation

Bremelanotide causes dose-dependent focal hyperpigmentation of the face, breasts, and gingiva in approximately 1% of women with prolonged use FDA label. This reflects MC1R saturation at the periphery. It is not a kidney effect, but it confirms that bremelanotide does reach peripheral melanocortin receptors, including those in renal tissue. Whether chronic peripheral MC1R occupancy at therapeutic doses produces any durable renal effect in humans remains unstudied.

Sex-Specific Pharmacokinetics: How Female Physiology Changes Renal Exposure

Women metabolize bremelanotide differently from men, and this matters for renal drug exposure.

Body Composition and Volume of Distribution

Bremelanotide is a peptide with a volume of distribution of approximately 22 liters after subcutaneous injection. Women have a higher percentage of body fat and lower lean mass per kilogram than men on average, which reduces the apparent volume of distribution per kilogram and can increase peak plasma concentration (Cmax) for the same 1.75 mg flat dose. A higher Cmax means higher renal filtration load per dose.

Menstrual Cycle Variation

No published data from the RECONNECT trials stratifies renal or hemodynamic outcomes by menstrual cycle phase. This is an evidence gap. Progesterone has natriuretic effects and alters renal vascular tone; estrogen modulates the renin-angiotensin-aldosterone system. It is biologically plausible that bremelanotide's blood pressure effect could differ in the luteal phase compared to the follicular phase, though this has not been studied directly. Women tracking their blood pressure with home cuffs may notice cycle-related variation independent of bremelanotide, which could confound self-assessment of the drug's hemodynamic impact.

Renal Clearance

Bremelanotide is cleared primarily by enzymatic hydrolysis of the peptide bond, with a terminal half-life of approximately 2.7 hours. Renal excretion of unchanged drug accounts for a minor fraction. Patients with moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m²) show modestly higher exposure (AUC approximately 1.6-fold higher), which may amplify both the blood pressure effect and any direct hemodynamic GFR depression FDA label.

Who Should Not Use Bremelanotide: Renal and Cardiovascular Contraindications

Absolute contraindications and strong cautions by clinical scenario:

| Patient Scenario | Guidance | |---|---| | Uncontrolled hypertension (SBP >140 or DBP >90 at baseline) | Do not prescribe; correct BP first | | eGFR <30 mL/min/1.73 m² (severe CKD or dialysis) | Contraindicated; no safety data | | eGFR 30-59 mL/min/1.73 m² (moderate CKD) | Use with caution; monitor BP before each dose | | Known cardiovascular or cerebrovascular disease | Contraindicated per FDA label | | Women prone to dehydration (breastfeeding, heat exposure) | Use with caution; ensure hydration | | Women on nephrotoxic medications (NSAIDs, calcineurin inhibitors) | Monitor eGFR; additive hemodynamic risk |

Life Stage Guide: Bremelanotide and Kidney Health Across Reproductive Years

Reproductive Years (Ages 18 to 45, Regular Cycles)

This is the approved indication. For a healthy premenopausal woman with normal blood pressure and eGFR above 60, the renal risk from infrequent bremelanotide use is low. Still, measure blood pressure before each dose, as instructed on the FDA label, and avoid use on days when you are dehydrated or ill.

Trying to Conceive

Bremelanotide is contraindicated in pregnancy. If you are trying to conceive, the drug must be stopped before a conception attempt because of uncertainty about the precise moment of implantation. The FDA label recommends using effective contraception during bremelanotide use and discontinuing the drug at least one week before attempting to conceive FDA label. The renal risk does not specifically change when trying to conceive, but the situation demands heightened vigilance about drug-free windows.

Perimenopause (Ages 40s to Early 50s)

Bremelanotide is approved for premenopausal women only. The RECONNECT trials excluded postmenopausal and perimenopausal women, so safety and efficacy data in women with fluctuating or declining estrogen are absent. Perimenopausal women have higher baseline cardiovascular risk than younger premenopausal women, and blood pressure often rises during the menopause transition. Prescribing bremelanotide off-label in perimenopause without baseline renal function testing and blood pressure monitoring would be particularly difficult to justify given the evidence gap. The 2023 Menopause Society position statement on sexual health does not endorse bremelanotide as a first-line option in perimenopause.

Postmenopause

Bremelanotide is not approved for postmenopausal women. Postmenopausal women are more likely to have CKD stage 2 or above, higher baseline blood pressure, and reduced renal reserve. Off-label use in this population carries disproportionate renal and cardiovascular risk relative to the premenopausal population in whom the drug was studied.

Pregnancy and Lactation Safety: A Required Section

Pregnancy: CONTRAINDICATED.

Bremelanotide caused fetal harm in animal studies at doses used for reproduction toxicology. In rats, fetal growth restriction and post-implantation loss were observed. No adequate and well-controlled studies exist in pregnant women. The FDA prescribing information classifies bremelanotide as contraindicated in pregnancy and states: "Based on animal data, bremelanotide may cause fetal harm." This is a Pregnancy Category X equivalent under the older classification, though under the PLLR system now used by the FDA, the label simply states risk under Pregnancy (8.1).

If you discover you are pregnant while using bremelanotide, stop the drug immediately and contact your obstetric provider. There is no established human teratogenicity registry for bremelanotide, so the true magnitude of human fetal risk is unknown.

Contraception requirement:

Women of reproductive age using bremelanotide should use reliable contraception throughout treatment FDA label. Because the drug is taken on demand rather than daily, it is easy to lose track of timing relative to ovulation. An intrauterine device, implant, or consistent hormonal method is preferable to barrier methods alone.

Lactation:

There are no data on the presence of bremelanotide or its metabolites in human breast milk, the effects on the breastfed infant, or the effects on milk production FDA label. Bremelanotide is a peptide and would be expected to undergo substantial degradation in the infant gastrointestinal tract if any transfer occurred, but "expected to degrade" is not the same as a demonstrated safety profile. The prescribing label advises against use during breastfeeding. Given the absence of human lactation data, this conservative approach is appropriate.

Postpartum renal note:

The postpartum period carries unique renal physiology. GFR normalizes from the hyperfiltration of pregnancy over roughly 6 to 12 weeks. Postpartum women who were hypertensive in pregnancy (preeclampsia, gestational hypertension) are at elevated long-term CKD risk. Introducing a blood-pressure-elevating drug in the postpartum or breastfeeding period, when renal recovery is ongoing, is inadvisable on current evidence.

PCOS, HSDD, and Kidney Considerations: A Specific Intersection

Women with polycystic ovary syndrome (PCOS) have a higher prevalence of hypertension, insulin resistance, and early-stage CKD than age-matched controls. A 2020 meta-analysis in BJOG found that women with PCOS had significantly higher rates of microalbuminuria, an early marker of glomerular damage, compared to controls. HSDD is also more prevalent in women with PCOS, partly because androgen dysregulation affects desire pathways.

This intersection matters: a woman with PCOS and HSDD who asks about bremelanotide may be at higher baseline renal risk than the typical RECONNECT trial participant. Renal function testing (eGFR, urine albumin-to-creatinine ratio) and blood pressure measurement before prescribing bremelanotide to a woman with PCOS is clinically warranted, even if not formally required by the label.

The Evidence Gap: What We Do Not Know About Bremelanotide and Female Kidney Health

WomanRx editorial board member Elena Vasquez, MD, summarizes the state of evidence this way: "The melanocortin renoprotection story is genuinely interesting science and may eventually lead somewhere clinically meaningful. But right now, every piece of human data we have on bremelanotide points toward modest renal stress, not renal protection, at the doses women actually use. Citing rat studies to reassure a patient with stage 3 CKD that PT-141 is safe for her kidneys would be a serious error."

Specific gaps in the current literature include:

• No published data on bremelanotide's renal effects stratified by menstrual cycle phase
• No long-term (beyond 52 weeks) renal function monitoring data from the RECONNECT program
• No human data on renal outcomes in women with eGFR 30 to 59 mL/min/1.73 m² using bremelanotide
• No data in perimenopausal or postmenopausal women
• No data in women with PCOS-associated microalbuminuria
• No data in women using concurrent nephrotoxic medications

Women have been historically underrepresented in drug trials focused on cardiorenal outcomes. The RECONNECT program was appropriately female-centered in its primary endpoints (desire, distress), but it was not powered or designed to detect renal endpoints. This is a research gap the field should address, particularly as off-label prescribing of compounded PT-141 expands in telehealth settings where baseline renal workup may not be standard.

Monitoring Protocol: Practical Steps Before and During Bremelanotide Use

Based on the FDA prescribing information and clinical reasoning from the RECONNECT safety data, a reasonable monitoring approach for a premenopausal woman with no known cardiovascular disease:

Before Starting

1. Measure blood pressure at rest. If consistently above 130/80 mmHg, optimize antihypertensive therapy before prescribing.
2. Order baseline serum creatinine, eGFR, and urine albumin-to-creatinine ratio (uACR), particularly if you have diabetes, PCOS, a family history of kidney disease, or prior gestational hypertension.
3. Review your full medication list for nephrotoxic drugs (NSAIDs, aminoglycosides, contrast agents, calcineurin inhibitors).
4. Confirm you are not pregnant and are using reliable contraception.

During Use

• Check blood pressure before each dose, as the FDA label instructs.
• Do not take a second dose within 24 hours.
• Stop the drug and contact your provider if you develop facial swelling, decreased urine output, or blood pressure consistently above 150/95 mmHg.
• Repeat eGFR and uACR at 6 months if you have any baseline renal risk factors.

Stopping

There is no taper required. Bremelanotide's half-life of approximately 2.7 hours means it clears within 24 hours. Stop immediately if pregnancy is confirmed or suspected.

Bremelanotide vs. Flibanserin: Kidney Risk Comparison

Women with HSDD often ask whether bremelanotide or flibanserin (Addyi) is safer for their kidneys. Flibanserin is taken daily at 100 mg orally and is metabolized hepatically, with no significant renal clearance concerns and no documented hemodynamic blood pressure effect. Bremelanotide's on-demand dosing avoids daily drug exposure but introduces an acute per-dose blood pressure spike that flibanserin does not.

For a woman with moderate CKD or borderline hypertension, flibanserin's renal profile is more favorable. For a woman who cannot take a daily pill reliably, the on-demand nature of bremelanotide is logistically appealing despite the blood pressure caveat. Shared decision-making with your provider, informed by your current blood pressure readings and eGFR, should drive this choice.